CANF:NYE-Can-Fite BioPharma Ltd (USD)

COMMON STOCK | Biotechnology | NYE

Last Closing Price

USD 0.87

Change

-0.02 (-2.10)%

Market Cap

USD 0.02B

Volume

0.04M

Avg Analyst Target

N/A

Avg User Target

USD
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

Can-Fite BioPharma Ltd (CANF) Stock Analysis:
Based on the Can-Fite BioPharma Ltd stock forecasts from 0 analysts, the average analyst target price for Can-Fite BioPharma Ltd is not available over the next 12 months. Can-Fite BioPharma Ltd’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Can-Fite BioPharma Ltd is Bearish, which is based on 2 positive signals and 5 negative signals. At the last closing, Can-Fite BioPharma Ltd’s stock price was USD 0.87. Can-Fite BioPharma Ltd’s stock price has changed by -4.29% over the past week, -10.21% over the past month and -57.92% over the last year.

About

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III ...Read More

Company Website : https://www.canfite.com

Address : 10 Bareket Street, Petah Tikva, Israel, 4951778

Employees : 8

Fiscal Year End : December

Currency: USD

Country : USA

Technical Indicators

Beta : 1.65

52 Week High : 2.62

Short Ratio : 2.63

52 Week Low : 0.78

Shorted Shares : 479,724

200 Day Moving Average : 1.33

Shorted Shares Previous Month : 770,090

50 Day Moving Average : 1.02

Short Percentage : 1.17%

Shares Held by Institutions : 1.40%

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-05-24 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
NVO Novo Nordisk A/S

+0.14 (+0.13%)

 USD244.30B 35.26 3.60
BHVN Biohaven Pharmaceutical Holdin..

-0.40 (-0.28%)

 USD10.16B N/A N/A
DNA Ginkgo Bioworks Holdings

-0.10 (-3.73%)

 USD4.64B N/A N/A
RCUS Arcus Biosciences Inc

-1.13 (-5.92%)

 USD1.51B 24.76 3.36
MYOV Myovant Sciences Ltd

-0.60 (-5.81%)

 USD1.00B N/A N/A
ADCT ADC Therapeutics SA

-0.46 (-6.13%)

 USD0.58B -99,999.99 N/A
PFNX Pfenex Inc

N/A

 USD0.44B 268.67 63.90
ZYME Zymeworks Inc

-0.32 (-5.22%)

 USD0.35B 300.20 N/A
LCTX Lineage Cell Therapeutics Inc

N/A

 USD0.21B 3.63 N/A
AMAM Ambrx Biopharma Inc.

-0.08 (-1.92%)

 USD0.16B N/A 0.13

ETFs Containing CANF

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -32.48% 67% D+ 14% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -32.48% 67% D+ 14% F
Trailing 12 Months  
Capital Gain -57.72% 48% F 7% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -57.72% 48% F 7% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -8.94% 22% F 7% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -8.94% 22% F 6% F
Risk Return Profile  
Volatility (Standard Deviation) 29.49% 89% B+ 38% F
Risk Adjusted Return -30.33% 19% F 9% F
Market Capitalization 0.02B 13% F 6% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 1.70 53% F 48% F
Price / Cash Flow Ratio -2.51 37% F 82% B-
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -123.34% 22% F 3% F
Return on Invested Capital -125.56% 17% F 2% F
Return on Assets -53.91% 20% F 1% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 2.63 63% D 41% F
Short Percent 1.17% 73% C 75% C
Beta 1.65 44% F 15% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date
New Post

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector